Evidence map›Paper›PMID 35510711›Full record

ArticleCancer medicine2022

Association of anticoagulant use with clinical outcomes from crizotinib in ALK- and ROS1-rearranged advanced non-small cell lung cancers: A retrospective analysis of PROFILE 1001.

Terry L Ng, David C C Tsui, Sherry Wang, Tiziana Usari, Tejas Patil, Keith Wilner, David R Camidge

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00585195 (PHASE 1 SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF-02341066, A MET/HGFR SELECTIVE TYROSINE KINASE INHIBITOR, ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00585195 phase1completednot on this map

Phase 1 safety, pharmacokinetic and pharmacodynamic study of pf-02341066, a met/hgfr selective tyrosine kinase inhibitor, administered orally to patients with advanced cancer

TypeinterventionalSponsorPfizerRan2006 to 2022Enrolled596ConditionsNon-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent, Non-Small Cell Lung Cancer ROS Marker Positive, Systemic Anaplastic Large-Cell LymphomaArmsPF-02341066, Rifampin, Itraconazole
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Non-bacterial thrombotic endocarditis inTranslational lung cancer research · 2024
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Terry L NgDivision of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, Canada.ORCID https://orcid.org/0000-0001-6128-3137
David C C TsuiDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
Sherry WangPfizer Oncology, San Francisco, California, USA.
Tiziana UsariPfizer, Milan, Italy.
Tejas PatilDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
Keith WilnerPfizer Oncology, La Jolla, California, USA.
David R CamidgeDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.

Funding

Joyce Zeff Chair in Lung Cancer ResearchPfizerUniversity of Colorado Cancer Center Thoracic Oncology Research Initiative
6 · The paper itself

Abstract

backgroundROS1- and ALK-rearranged advanced NSCLCs are associated with increased thromboembolic risk. We hypothesized that a prothrombotic phenotype offers an evolutionary advantage to subsets of these cancers. The impact of this phenotype could alter outcomes from targeted therapy.

methodsIn a retrospective analysis of ROS1- and ALK-rearranged NSCLCs treated with crizotinib in a phase 1 trial, we compared progression-free survival (PFS) and objective response rate (ORR) based on the history of anticoagulation use (a possible surrogate of thromboembolism) at baseline (within 90 days before study enrollment) or within 90 days of study treatment.

resultsTwelve out of 53 (22.6%) ROS1- and 39 out of 153 (25.5%) ALK-rearranged NSCLCs received anticoagulation before or during the trial. Most ROS1 and ALK patients on anticoagulation received low-molecular-weight heparin (75% and 64.1%, respectively). In the ROS1-rearranged group, the median PFS (95% CI) values were 5.1 (4.4-14.4) and 29.0 (16.5-48.8) months, and the ORR values were 41.7% (95% CI: 15.2 to 72.3) and 80.5% (95% CI: 65.1 to 91.2) among those with and without anticoagulation treatment, respectively. In the ALK-rearranged group, the median PFS (95% CI) was 7.1 (5.4-7.7) and 12.0 (9.4-18.3) months, and the ORR was 41% (95% CI: 25.6 to 57.9) and 74.3% (95% CI: 65.3 to 82.1) among those with and without anticoagulation, respectively.

conclusionsAnticoagulation (as a potential surrogate of a prothrombotic subset) in ROS1- and ALK-rearranged NSCLCs may be associated with a lower PFS and ORR to crizotinib. CLINICALTRIAL: gov: NCT00585195.

Indexed as

Carcinoma, Non-Small-Cell LungCrizotinibLung NeoplasmsGene RearrangementHumansProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene ProteinsRetrospective StudiesCrizotinibProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene ProteinsROS1 protein, humanALKcrizotiniblung cancerROS1thromboembolism

Identifiers

PMID35510711
PMCPMC9741966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.